Alembic Pharma Wins USFDA Nod for Generic Mental Health Drug

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its generic mental health drug — Paroxetine extended-release tablets, a medication commonly used to treat mental health conditions.

The approval is for Paroxetine extended-release tablets USP, 12.5 mg. This drug is a generic equivalent of Paxil CR and is prescribed for conditions such as depression, anxiety disorders, panic disorder, and premenstrual dysphoric disorder.

This development strengthens Alembic’s position in the United States pharmaceutical market, which remains one of the most important and competitive globally. By adding this product to its portfolio, the company is expanding its presence in the mental health treatment segment, where demand continues to remain steady.

With this approval, Alembic Pharmaceuticals now has a total of over 200 ANDA approvals from the USFDA, including both final and tentative clearances. The company has been consistently focusing on growing its generics business in regulated markets, especially in the US.

Also Read: How Pharma Authentication Tech Enhances ROI and Safety

Industry experts see this approval as another step forward for Indian pharmaceutical companies, which have been steadily increasing their footprint in the global generics market. Their ability to offer cost-effective medicines while meeting strict regulatory standards has helped them remain competitive.

For Alembic, this approval is not just about adding another product. It reflects a broader strategy of targeting therapies that have long-term demand and stable market potential. Mental health treatments fall squarely into this category, making them a key area of focus.

Overall, the USFDA approval is expected to support Alembic’s growth in international markets and strengthen its product pipeline. As the company continues to pursue more approvals, it is clearly aiming to build a stronger and more diversified presence in the global pharmaceutical industry.